Full-Time

ML & Molecular Simulation Scientist

Genesis Molecular AI

Genesis Molecular AI

51-200 employees

AI-driven drug discovery platform for pharma

No salary listed

San Mateo, CA, USA

In Person

On-site in San Mateo, California.

PhD

Category
AI & Machine Learning (1)
Required Skills
Python
Neural Networks
PyTorch
Machine Learning
NumPy

Get referred to Genesis Molecular AI

See people who can refer or advise you

Requirements
  • Practical experience with 3D machine learning – geometric deep learning, graph neural networks, equivariant architectures (e.g., SE(3)/E(3) networks), or diffusion models applied to molecular data
  • PhD (preferred) in computer science, machine learning, chemical engineering, biophysics, physics, or a closely related field; postdoctoral or industry experience is a plus
  • Deep, hands-on expertise in molecular simulation, including molecular dynamics, enhanced sampling, and/or free energy methods using tools such as GROMACS, AMBER, OpenMM, or NAMD
  • Familiarity with structure-based drug design workflows: docking, binding site analysis, protein-ligand interaction modeling using tools such as MOE, or PyMOL
  • Proficiency in Python and scientific computing libraries (PyTorch, JAX, NumPy, MDAnalysis, RDKit); comfort with HPC environments and scripting for large-scale simulation workflows
  • A track record of applying computational methods to real scientific problems, demonstrated through publications, open-source contributions, or industry impact
  • Collaborative, curious, and able to move between rigorous method development and fast-paced discovery work
Responsibilities
  • Build and apply ML models informed by 3D structural data, including geometric deep learning, equivariant neural networks, and diffusion-based generative models for molecular design and property prediction
  • Integrate physics-based and ML + data-driven approaches, combining force field methods, quantum chemistry, and structure-based design with modern ML to improve accuracy and throughput
  • Develop and apply simulation methods spanning molecular dynamics, enhanced sampling (metadynamics, replica exchange, umbrella sampling), and free energy calculations (FEP/TI) to support active drug discovery programs
  • Contribute to the GEMS platform, improving our generative AI and scoring capabilities, focusing on 3D methods; strengthen ML and physics-based scoring functions (and their intersection), build next-gen force fields
  • Work directly with CADD and discovery scientists to apply computational methods across the drug discovery pipeline, from target structure analysis through lead optimization
  • Stay current with the field, implementing and adapting methods from the latest literature in geometric ML, biomolecular simulation, and computational drug design
  • Communicate scientific results clearly to multidisciplinary teams, including experimental chemists and biologists
Desired Qualifications
  • Familiarity with cheminformatics and ADMET property prediction
  • Contributions to open-source simulation or ML tooling

Genesis Molecular AI uses artificial intelligence to speed up drug discovery for the pharmaceutical industry. It combines 3D spatial graph modeling and advanced molecular simulation to generate and evaluate potential drug candidates and to uncover novel protein targets. The platform translates complex molecular data into actionable candidates by representing molecules in 3D graphs and running simulations to predict how they bind to target proteins, helping partners identify promising therapies. The company differentiates itself by integrating 3D spatial graph modeling with detailed molecular simulations to explore untapped chemical space and novel targets, and by focusing on business-to-business partnerships with pharma and biotech companies. Its goal is to accelerate drug discovery for partners by delivering AI-generated candidates and enabling faster progression from target to therapy.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$400.1M

Headquarters

Burlingame, California

Founded

2019

Get referred to Genesis Molecular AI

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 Incyte expansion delivered $120 million upfront, including $40 million equity.
  • Incyte will share proprietary data and fund compute, improving Genesis model training.
  • Genesis claims Pearl outperformed all cofolding models on OpenBind in October 2025.

What critics are saying

  • Incyte owns exclusive commercialization rights, limiting Genesis’s downstream capture through 2026.
  • OpenAI, Recursion, and Schrödinger intensify AI-drug-discovery competition for talent and partners.
  • If Pearl and GEMS miss wet-lab success, Genesis becomes a services vendor.

What makes Genesis Molecular AI unique

  • GEMS combines foundation models, physical simulation, and proprietary experimental data.
  • Genesis secured Incyte’s exclusive 2025 and expanded 2026 collaboration rights.
  • Sergey Edunov joined in December 2025 to scale foundation-model leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Parental Leave

Disability Insurance

Life Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Business Wire
May 21st, 2026
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

Incyte and Genesis expand molecular AI collaboration to accelerate 
drug discovery

Business News Today
Dec 3rd, 2025
Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard?

Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard? Genesis Molecular AI hires Meta's Llama leader Sergey Edunov to lead foundation models. Discover how this move strengthens its AI drug discovery platform. Genesis Molecular AI, the foundation model-driven drug design firm formerly known as Genesis Therapeutics, has appointed Sergey Edunov as Senior Vice President of Foundation Models. The executive hire marks a strategic inflection point as the company prepares to scale its GEMS platform and unveil new generative model research at the NeurIPS 2025 conference. Sergey Edunov is best known for his leadership role in developing Meta Platforms' Llama 2 and Llama 3 large language models. He brings over two decades of software engineering and AI research experience, having previously served as Senior Director of AI Research in Meta's generative AI division. His arrival at Genesis Molecular AI signals the firm's ambition to compete at the highest levels of foundation model development applied to molecular design.

Latest Nigerian News
Aug 7th, 2025
Genesis Therapeutics raises $52M for AI drug discovery

Genesis Therapeutics has successfully raised a $52 million A round to advance its AI-focused drug discovery mission. The company employs a novel simulation approach and a cross-disciplinary team to efficiently explore the vast array of potential medicinal molecules.

Today Media
May 28th, 2025
Incyte aims to accelerate drug research with AI collaboration

Earlier this year, Incyte inked a deal with Genesis Therapeutics to use the biotech company's AI platform to develop small molecule medicines.

Fierce Biotech
Feb 20th, 2025
Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.